Inovio Pharmaceuticals

Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target prostate, breast, and lung cancers as well as HIV, influenza, malaria and hepatitis. Partners and collaborators include Roche, the University of Pennsylvania, Merck, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative

Type
Public
HQ
Blue Bell, US
Size (employees)
157 (est)
Website
inovio.com
Inovio Pharmaceuticals is headquartered in Blue Bell, US

Key People at Inovio Pharmaceuticals

J. Joseph Kim

J. Joseph Kim

CEO

Inovio Pharmaceuticals Office Locations

Inovio Pharmaceuticals has an office in Blue Bell
Blue Bell, US (HQ)
1787 Sentry Parkway West

Inovio Pharmaceuticals Data and Metrics

Inovio Pharmaceuticals Financial Metrics

Inovio Pharmaceuticals's revenue was reported to be $10.4 m in Q1, 2017
USD

Revenue (Q1, 2017)

10.4 m

EBIT (Q1, 2017)

(21.9 m)

Market capitalization (21-Jul-2017)

450.3 m

Cash (31-Mar-2017)

22.9 m
Inovio Pharmaceuticals's current market capitalization is $450.3 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

13.5 m10.5 m40.6 m8.5 m

Revenue growth, %

(22%)288%(79%)

Operating expense total

33 m50 m74.9 m30.9 m

EBIT

(19.5 m)(39.5 m)(34.3 m)(22.4 m)

EBIT margin, %

(145%)(378%)(85%)(263%)

Interest income

8.6 k113.2 k194.5 k191.5 k

Net Income

(66.1 m)(36.1 m)(29.1 m)(73.7 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

3.8 m1.8 m5.2 m5.3 m24.2 m8.1 m6.2 m12.5 m10.4 m

R&D expense

9.6 m7 m9.4 m16.7 m16.1 m18.2 m19.6 m27 m24.5 m

General and administrative expense

4.3 m3.2 m4.1 m4.7 m4.4 m5.4 m5.8 m5.8 m7.8 m

Operating expense total

14 m10.2 m13.5 m21.4 m20.5 m23.6 m25.4 m32.7 m32.3 m

EBIT

(10.2 m)(8.3 m)(8.4 m)(15.1 m)3.7 m(15.5 m)(18.2 m)(20.2 m)(21.9 m)

EBIT margin, %

(267%)(453%)(162%)(286%)15%(191%)(294%)(161%)(211%)

Interest income

69 k97.2 k138.3 k146.3 k215 k333.1 k341.1 k391.6 k340.3 k

Income tax expense

1.8 m

Net Income

(10.7 m)(7.2 m)(10.6 m)(6.2 m)5.6 m(8 m)(18.7 m)(20.8 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

33.7 m40.5 m57.6 m19.1 m

Accounts Receivable

3.3 m2.8 m7.3 m15.8 m

Inventories

637.4 k798 k917.3 k1.7 m

Current Assets

58.7 m98.9 m171.9 m124.6 m

Goodwill

10.1 m10.1 m10.1 m10.5 m

Total Assets

88.3 m131.8 m213.8 m173.7 m

Accounts Payable

5.4 m6.4 m13.1 m19.6 m

Current Liabilities

29 m14 m31.5 m43.8 m

Total Liabilities

50.3 m

Additional Paid-in Capital

348.1 m443.3 m534 m556.7 m

Retained Earnings

(295.8 m)(331.9 m)(361.1 m)(434.8 m)

Total Equity

52.9 m111.5 m175.9 m123.4 m

Financial Leverage

1.7 x1.2 x1.2 x1.4 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

88.5 m70.7 m26.1 m70.3 m85.5 m41.6 m28.5 m23.3 m22.9 m

Accounts Receivable

2.9 m1.6 m3.3 m5.6 m11 m11.2 m10.4 m17.5 m9.9 m

Current Assets

112.9 m104.6 m87.3 m162.1 m184.1 m160.6 m148 m140.2 m106.8 m

Goodwill

10.1 m10.1 m10.1 m10.1 m10.1 m10.1 m10.5 m10.5 m10.5 m

Total Assets

142.2 m134.5 m117.9 m201.7 m230.8 m211.3 m204 m194.5 m153.3 m

Accounts Payable

5.3 m4.7 m4.4 m6.1 m10.5 m12.1 m12.7 m16.2 m14.5 m

Current Liabilities

11.6 m8.9 m8.2 m14.5 m18.3 m33.4 m35.5 m41.4 m40 m

Common Stock

60.3 k60.5 k60.7 k71.8 k72.2 k72.3 k73.5 k74 k74.6 k

Additional Paid-in Capital

439.1 m441.3 m445.7 m529.6 m532.6 m537.1 m546.3 m552.8 m563.2 m

Retained Earnings

(317.3 m)(324.5 m)(342.5 m)(348.7 m)(343.1 m)(369.1 m)(387.8 m)(408.6 m)(458.2 m)

Total Equity

181 m193.4 m171.2 m162.1 m147 m105.9 m

Financial Leverage

1.1 x1.2 x1.2 x1.3 x1.3 x1.4 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(66.1 m)(36.1 m)(29.1 m)(73.7 m)

Depreciation and Amortization

2.1 m1.6 m1.9 m3.1 m

Accounts Receivable

(2.5 m)499.2 k(4.5 m)(8.5 m)

Inventories

(229.7 k)(160.5 k)(119.3 k)(831.8 k)

Accounts Payable

2.2 m1.5 m6.5 m6.4 m

Cash From Operating Activities

(15.4 m)(29.8 m)(12.4 m)(62.6 m)

Cash From Investing Activities

(9.2 m)(35.8 m)(54.8 m)16.3 m

Cash From Financing Activities

52.7 m72.5 m84.4 m7.8 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(10.7 m)(7.2 m)(10.6 m)(6.2 m)5.6 m(8 m)(18.7 m)(20.8 m)

Accounts Receivable

2.9 m1.6 m3.3 m5.6 m11 m11.2 m10.4 m17.5 m9.9 m

Accounts Payable

5.3 m4.7 m4.4 m6.1 m10.5 m12.1 m12.7 m16.2 m14.5 m
USDY, 2017

Revenue/Employee

66.1 k

Financial Leverage

1.4 x

Inovio Pharmaceuticals Operating Metrics

FY, 2016

Patents Issued

620

Inovio Pharmaceuticals Market Value History

Inovio Pharmaceuticals Online and Social Media Presence

Inovio Pharmaceuticals News and Updates

Inovio Pharmaceuticals Company Life and Culture

You may also be interested in